Male |
118 (89.4) |
14 (10.6) |
0.012 |
Age (yr) (median, IQR) |
10.5 (8.3-12.5) |
12.2 (9.6-14.4) |
0.005 |
Duration of follow up (yr) (median, IQR) |
2.1 (1.0-5.1) |
3.3 (1.5-6.4) |
0.180 |
Tobacco exposure |
113 (85.6) |
19 (14.4) |
0.498 |
Aeroallergen sensitisation |
99 (90.0) |
11 (10.0) |
0.021 |
Asthma therapy |
|
|
0.059 |
As needed SABA
|
51 (91.1)
|
5 (8.9)
|
|
ICS use
|
127 (83.1)
|
26 (16.9)
|
|
ICS monotherapy
|
99 (83.2)
|
20 (16.8)
|
|
LTRA monotherapy
|
14 (77.8)
|
4 (22.2)
|
|
ICS+LTRA
|
16 (94.2)
|
1 (5.8)
|
|
ICS+LABA
|
12 (70.6)
|
5 (29.4)
|
|
ICS+LABA+LTRA
|
0 (0.0)
|
1 (100)
|
|
Asthma severity |
|
|
0.167 |
İntermittent
|
53 (89.8)
|
6 (10.2)
|
|
Mild persistent
|
95 (81.2)
|
22 (18.8)
|
|
Moderate persisitent
|
33 (94.3)
|
2 (5.7)
|
|
Severe persistent
|
11 (64.7)
|
6 (35.3)
|
|
Allerjic rhinitis coexistent |
81 (85.3) |
14 (14.7) |
0.695 |
FeNO (ppb) |
19 (14-28) |
19 (16-26) |
0.654 |
PACT |
23 (19-26) |
18 (13.5-21) |
<0.001 |
ACT |
22.5 (19.25-24.75) |
15 (14-19) |
<0.001 |
PAQLQ (median, IQR) |
6.1 (5.2-6.6) |
4.8 (3.9-5.6) |
<0.001 |
Symptoms |
5.4 (4.6-6.6) |
3.8 (2.8-5.2) |
<0.001 |
Emotional functions |
6.2 (5.4-6.7) |
4.6 (3.8-5.4) |
<0.001 |
Activity limitation |
6.4 (5.2-7.0) |
5.5 (4.5-6.2) |
0.001 |
Spirometry (median, IQR) |
|
|
|
FEV1 (expected %)
|
93 (87-103)
|
94 (83-103)
|
0.757
|
FEV1/FVC (ratio)
|
0.99 (0.93-1.05)
|
0.97 (0.94-1.05)
|
0.724
|
FEF25-75 (expected %)
|
92 (79-112)
|
88 (79-106)
|
0.485
|